Drug news

NICE does not recommend Ocrevus as a treatment for Multiple Sclerosis.- Roche

Read time: 1 mins

Last updated:6th Apr 2018

Published:6th Apr 2018

Source: Pharmawand

The National Institute for Health and Care Excellence (NICE) in its draft guidance has rejected Ocrevus (ocrelizumab) from Roche, as a treatment for relapsing forms of Multiple Sclerosis,commenting that there are already eight other drugs recommended for the disease.

Roche had presented no evidence of direct comparison with any of the recommended and approved drugs and it was unclear to NICE that Ocrevus was any better than any of them in slowing disease control.

Learning Zone Homepage

Multiple Sclerosis (MS) Learning Zone

Choosing the right treatment is critical to managing multiple sclerosis (MS). Consider your options with the latest data from over 40 MS clinical trial and congress resources.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

The FDA has approved the Esprit BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with chronic limb-threatening ischemia below-the-knee

Abbott announced that the FDA has approved the Esprit BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with chronic limb-threatening ischemia (CLTI) below-the-knee (BTK)

2 mins

Drug news

Promising findings in phase IIb/III clinical trial of NRX 101 vs. lurasidone for treatment of suicidal bipolar depression

NRx Pharmaceuticals, Inc. announced that its Breakthrough Therapy designated investigational drug NRX 101 vs lurasidone demonstrated a promising, though not yet statistically significant 33% reduction in suicidality together with a 70% reduction (P=.076) reduction in symptoms of akathisia – a side effect of antidepressants that is closely linked to suicide and considered a medical emergency

1 min

Drug news

FDA approval of Ingrezza Sprinkle (valbenazine) capsules for the treatment of adults with tardive dyskinesia and chorea associated with Huntington's disease

Neurocrine Biosciences, Inc. announced the FDA has approved Ingrezza Sprinkle (valbenazine) capsules, a new oral granules formulation of Ingrezza (valbenazine) capsules prescribed for the treatment of adults with tardive dyskinesia and chorea associated with Huntington's disease

1 min

See all news